# Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)

> **NCT01004770** · PHASE1,PHASE2 · COMPLETED · sponsor: **GE Healthcare** · enrollment: 50 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GE-145 (AN113111) Injection
- **DRUG:** Visipaque (iodixanol) Injection

## Key facts

- **NCT ID:** NCT01004770
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-02
- **Final completion:** 2010-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2012-04-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01004770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01004770, "Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01004770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*